Next Article in Journal
Protective Effects of Probiotics on Cognitive and Motor Functions, Anxiety Level, Visceral Sensitivity, Oxidative Stress and Microbiota in Mice with Antibiotic-Induced Dysbiosis
Next Article in Special Issue
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Previous Article in Journal
Association of Nonalcoholic Hepatic Fibrosis with Body Composition in Female and Male Psoriasis Patients
Previous Article in Special Issue
Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report
Systematic Review

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Chair and Department of Psychology, Medical University of Lublin, 20-093 Lublin, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Shih-Jen Tsai
Life 2021, 11(8), 765; https://doi.org/10.3390/life11080765
Received: 29 June 2021 / Revised: 24 July 2021 / Accepted: 26 July 2021 / Published: 29 July 2021
(This article belongs to the Special Issue Novel Pharmacological Approaches to the Treatment of Depression)
Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic substances for the treatment of depression. A literature search of the PubMed/MEDLINE database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, MDMA, DMT, or LSD for the treatment of depression symptoms. Some psychedelics, especially psilocybin, demonstrated an ability to reduce depressive symptoms as measured by several psychological scales, which was often sustained for months after the last psychedelic session. Moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. None of the studies reported any serious adverse events associated with psychedelic administration. The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future. View Full-Text
Keywords: psychedelics; depression; serotonergic hallucinogens; psilocybin; MDMA; LSD; DMT psychedelics; depression; serotonergic hallucinogens; psilocybin; MDMA; LSD; DMT
Show Figures

Figure 1

MDPI and ACS Style

Psiuk, D.; Nowak, E.; Cholewa, K.; Łopuszańska, U.; Samardakiewicz, M. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life 2021, 11, 765. https://doi.org/10.3390/life11080765

AMA Style

Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life. 2021; 11(8):765. https://doi.org/10.3390/life11080765

Chicago/Turabian Style

Psiuk, Dominika, Emilia Nowak, Krystian Cholewa, Urszula Łopuszańska, and Marzena Samardakiewicz. 2021. "The Potential Role of Serotonergic Hallucinogens in Depression Treatment" Life 11, no. 8: 765. https://doi.org/10.3390/life11080765

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop